Tetronothiodin, a novel cholecystokinin type-B receptor antagonist produced by Streptomyces sp. NR0489. II. Isolation, characterization and biological activities.

Tatsuo Ohtsuka, HIROMICHI KOTAKI, Noboru Nakayama, Yoshiko Itezono, Nobuo Shimma, Tsutomu Kudoh, Toshikazu Kuwahara, Mikio Arisawa, Kazuteru Yokose, Haruo Seto

The Journal of Antibiotics · 1993 · 38 citations · 13 references

DOIFull text

Open access

Concepts

Abstract

A novel cholecystokinin type-B receptor antagonist named tetronothiodin has been isolated by column chromatography and preparative HPLC from the fermentation broth of Streptomyces sp. NR0489. Tetronothiodin inhibited the binding of CCK8 (C-terminal octapeptide of cholecystokinin) to rat cerebral cortex membranes (CCK type-B receptors) with an IC50 of 3.6 nM, whereas it did not inhibit CCK8 binding to rat pancreatic membranes (CCK type-A receptors). It also inhibited CCK8 induced Ca2+ mobilization in GH3 cells, a rat anterior pituitary cell line, but was without effect on the basal cytosolic Ca2+ concentration. This finding indicated tetronothiodin was an antagonist of CCK type-B receptors.

References

13